Pharmamarketeer

Novartis phase III ASCLEPIOS I & II studies of ofatumumab versus Aubagio to treat relapsing forms MS meets primary endpoints

Novartis announced positive results for ofatumumab (OMB157) from the phase III ASCLEPIOS I and II studies. In both head─to─head studies, ofatumumab demonstrated superiority over Aubagio (teriflunomide) in patients

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl